{"analyses":[{"ciLowerLimit":"1.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.60","groupDescription":"This analysis is for Not Hispanic or Latino participants","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"1.31"},{"ciLowerLimit":"0.89","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.31","groupDescription":"This analysis is for Hispanic or Latino participants.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Cox Proportional Hazard","paramValue":"1.08"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.0","upperLimit":"8.0","value":"7.0"},{"groupId":"OG001","lowerLimit":"7.0","upperLimit":"10.0","value":"9.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.0","upperLimit":"8.0","value":"7.0"},{"groupId":"OG001","lowerLimit":"6.0","upperLimit":"9.0","value":"7.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"268"}],"units":"Participants"}],"title":"Hispanic or Latino"}],"denoms":[{"counts":[{"groupId":"OG000","value":"509"},{"groupId":"OG001","value":"508"}],"units":"Participants"}],"description":"Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen and no longer requires ongoing medical care.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEDIAN","populationDescription":"The intent-to-treat (ITT) population includes all participants who were randomized and for whom ethnicity was reported","reportingStatus":"POSTED","timeFrame":"Day 1 through Day 29","title":"Time to Recovery by Ethnicity","type":"PRIMARY","unitOfMeasure":"Days"}